Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice

Retinitis pigmentosa (RP) is a progressive retinal dystrophy that causes visual impairment and eventual blindness. Retinal prostheses are the best currently available vision-restoring treatment for RP, but only restore crude vision. One possible contributing factor to the poor quality of vision achi...

Full description

Bibliographic Details
Main Authors: John Martin Barrett, Patrick eDegenaar, Evelyne eSernagor
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-08-01
Series:Frontiers in Cellular Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fncel.2015.00330/full
_version_ 1819086859793334272
author John Martin Barrett
Patrick eDegenaar
Evelyne eSernagor
author_facet John Martin Barrett
Patrick eDegenaar
Evelyne eSernagor
author_sort John Martin Barrett
collection DOAJ
description Retinitis pigmentosa (RP) is a progressive retinal dystrophy that causes visual impairment and eventual blindness. Retinal prostheses are the best currently available vision-restoring treatment for RP, but only restore crude vision. One possible contributing factor to the poor quality of vision achieved with prosthetic devices is the pathological retinal ganglion cell (RGC) hyperactivity that occurs in photoreceptor dystrophic disorders. Gap junction blockade with meclofenamic acid (MFA) was recently shown to diminish RGC hyperactivity and improve the signal-to-noise ratio (SNR) of RGC responses to light flashes and electrical stimulation in the rd10 mouse model of RP. We sought to extend these results to spatiotemporally patterned optogenetic stimulation in the faster-degenerating rd1 model and compare the effectiveness of a number of drugs known to disrupt rd1 hyperactivity.We crossed rd1 mice with a transgenic mouse line expressing the light-sensitive cation channel channelrhodopsin2 (ChR2) in RGCs, allowing them to be stimulated directly using high-intensity blue light. We used 60-channel ITO multielectrode arrays to record ChR2-mediated RGC responses from wholemount, ex-vivo retinas to full-field and patterned stimuli before and after application of MFA, 18-ß-glycyrrhetinic acid (18BGA, another gap junction blocker) or flupirtine (Flu, a Kv7 potassium channel opener). All three drugs decreased spontaneous RGC firing, but 18BGA and Flu also decreased the sensitivity of RGCs to optogenetic stimulation. Nevertheless, all three drugs improved the SNR of ChR2-mediated responses. MFA also made it easier to discern motion direction of a moving bar from RGC population responses.Our results support the hypothesis that reduction of pathological RGC spontaneous activity characteristic in retinal degenerative disorders may improve the quality of visual responses in retinal prostheses and they provide insights into how best to achieve this for optogenetic prostheses.
first_indexed 2024-12-21T21:26:57Z
format Article
id doaj.art-af49e7e14d2b4b20acc6aaa7de1c9d51
institution Directory Open Access Journal
issn 1662-5102
language English
last_indexed 2024-12-21T21:26:57Z
publishDate 2015-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Cellular Neuroscience
spelling doaj.art-af49e7e14d2b4b20acc6aaa7de1c9d512022-12-21T18:49:44ZengFrontiers Media S.A.Frontiers in Cellular Neuroscience1662-51022015-08-01910.3389/fncel.2015.00330156972Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 miceJohn Martin Barrett0Patrick eDegenaar1Evelyne eSernagor2Newcastle UniversityNewcastle UniversityNewcastle UniversityRetinitis pigmentosa (RP) is a progressive retinal dystrophy that causes visual impairment and eventual blindness. Retinal prostheses are the best currently available vision-restoring treatment for RP, but only restore crude vision. One possible contributing factor to the poor quality of vision achieved with prosthetic devices is the pathological retinal ganglion cell (RGC) hyperactivity that occurs in photoreceptor dystrophic disorders. Gap junction blockade with meclofenamic acid (MFA) was recently shown to diminish RGC hyperactivity and improve the signal-to-noise ratio (SNR) of RGC responses to light flashes and electrical stimulation in the rd10 mouse model of RP. We sought to extend these results to spatiotemporally patterned optogenetic stimulation in the faster-degenerating rd1 model and compare the effectiveness of a number of drugs known to disrupt rd1 hyperactivity.We crossed rd1 mice with a transgenic mouse line expressing the light-sensitive cation channel channelrhodopsin2 (ChR2) in RGCs, allowing them to be stimulated directly using high-intensity blue light. We used 60-channel ITO multielectrode arrays to record ChR2-mediated RGC responses from wholemount, ex-vivo retinas to full-field and patterned stimuli before and after application of MFA, 18-ß-glycyrrhetinic acid (18BGA, another gap junction blocker) or flupirtine (Flu, a Kv7 potassium channel opener). All three drugs decreased spontaneous RGC firing, but 18BGA and Flu also decreased the sensitivity of RGCs to optogenetic stimulation. Nevertheless, all three drugs improved the SNR of ChR2-mediated responses. MFA also made it easier to discern motion direction of a moving bar from RGC population responses.Our results support the hypothesis that reduction of pathological RGC spontaneous activity characteristic in retinal degenerative disorders may improve the quality of visual responses in retinal prostheses and they provide insights into how best to achieve this for optogenetic prostheses.http://journal.frontiersin.org/Journal/10.3389/fncel.2015.00330/fullMeclofenamic AcidRetinal Degenerationspontaneous activityoptogeneticsRetinal prosthesisFlupirtine
spellingShingle John Martin Barrett
Patrick eDegenaar
Evelyne eSernagor
Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
Frontiers in Cellular Neuroscience
Meclofenamic Acid
Retinal Degeneration
spontaneous activity
optogenetics
Retinal prosthesis
Flupirtine
title Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
title_full Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
title_fullStr Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
title_full_unstemmed Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
title_short Blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
title_sort blockade of pathological retinal ganglion cell hyperactivity improves optogenetically evoked light responses in rd1 mice
topic Meclofenamic Acid
Retinal Degeneration
spontaneous activity
optogenetics
Retinal prosthesis
Flupirtine
url http://journal.frontiersin.org/Journal/10.3389/fncel.2015.00330/full
work_keys_str_mv AT johnmartinbarrett blockadeofpathologicalretinalganglioncellhyperactivityimprovesoptogeneticallyevokedlightresponsesinrd1mice
AT patrickedegenaar blockadeofpathologicalretinalganglioncellhyperactivityimprovesoptogeneticallyevokedlightresponsesinrd1mice
AT evelyneesernagor blockadeofpathologicalretinalganglioncellhyperactivityimprovesoptogeneticallyevokedlightresponsesinrd1mice